<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561626</url>
  </required_header>
  <id_info>
    <org_study_id>07-3-088</org_study_id>
    <nct_id>NCT00561626</nct_id>
  </id_info>
  <brief_title>Effects of High-fat and Low-fat Diet on the Gut</brief_title>
  <official_title>Effects of a High-fat and a Low-fat Diet on Early Biomarkers of Metabolic Stress in Blood and Gene Expression in the Small Intestine of Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The prevalence of the metabolic syndrome is strongly increasing in developed&#xD;
      countries. The role of the small intestine seems important in the development of the&#xD;
      metabolic syndrome. Although it is known that a high-fat Western-style of diet has&#xD;
      deleterious effects on (post-prandial) lipidemia and glucose homeostases, effects of such a&#xD;
      diet on the small intestine is not known. To elucidate the role of the small intestine on the&#xD;
      early development of the metabolic syndrome, the effects of a high-fat (HF) and a low-fat&#xD;
      (LF) diet will be examined on gene expression in the small intestine and early biomarkers in&#xD;
      blood of healthy subjects.&#xD;
&#xD;
      Objective: The objective of this study is to compare in healthy subjects the effects of a HF&#xD;
      diet (40 En% fat) with those of a LF diet (20 En% fat) on early biomarkers and parameters of&#xD;
      metabolic stress in blood and on expression of genes in the small intestine.&#xD;
&#xD;
      Additional research objectives are:&#xD;
&#xD;
        -  To compare the diet-induced changes in transcriptome profile of the small intestine with&#xD;
           more easily accessible peripheral blood mononuclear cells (PBMC)&#xD;
&#xD;
        -  To establish effects of HF and LF diet on basal gut permeability and after a&#xD;
           chenodeoxycholic acid (CDCA) load (second hit).&#xD;
&#xD;
      Study design: Randomised crossover design. The duration of the experimental periods (HF and&#xD;
      LF diet) will be 28 days, separated by a wash out period of at least 3 weeks. At day 21 of&#xD;
      each intervention period a postprandial test will be performed and duodenum biopsies will be&#xD;
      taken. At day 25 and 28 of each intervention period, respectively, basal gut permeability and&#xD;
      gut permeability after a CDCA load will be determined with a sugar recovery test.&#xD;
&#xD;
      Study population: Ten healthy men in the age of 18-60 years, without a history of any&#xD;
      gastrointestinal disorders or complaints.&#xD;
&#xD;
      Intervention: Subjects will consume in random order:&#xD;
&#xD;
        -  a HF diet (40 En% fat, 45 En% carbohydrates and 15 En% proteins)&#xD;
&#xD;
        -  a LF diet (20 En% fat, 65 En% carbohydrates and 15 En% proteins)&#xD;
&#xD;
      Primary study parameters/endpoints: Potential early biomarkers of the metabolic syndrome in&#xD;
      blood and gene expression profiles in the small intestine.&#xD;
&#xD;
      Secondary study parameters/endpoints: Parameters of the metabolic syndrome in blood, gene&#xD;
      expression profiles in PBMC and gut permeability.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>potential early biomarkers in plasma</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gene expression in the small intestine and in peripheral blood mononuclear cells (PBMC)</measure>
    <time_frame>3 weken</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut permeability</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>high fat diet followed by low fat diet</intervention_name>
    <description>High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>low fat diet followed by high fat diet</intervention_name>
    <description>Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 and 65 years&#xD;
&#xD;
          -  body mass index (BMI) between 18 and 30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI ≤ 18 and ≥ 25 kg/m2&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Serum Total cholesterol &gt; 8.0 mmol/L&#xD;
&#xD;
          -  Fasting glucose &gt; 7.0 mmol/L&#xD;
&#xD;
          -  Use of any medication&#xD;
&#xD;
          -  Active cardiovascular diseases like congestive heart failure or recent (&lt;6 months)&#xD;
             event (acute myocardial infarction, CVA)&#xD;
&#xD;
          -  Gastrointestinal diseases (like celiac disease, inflammatory bowel disease, irritable&#xD;
             bowel disease and food allergies) or a history of any gastrointestinal disorders or&#xD;
             complaints&#xD;
&#xD;
          -  Pre-existing gallbladder disease&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Familial hypercholesterolemia&#xD;
&#xD;
          -  Severe medical conditions that might interfere with the study such as epilepsy,&#xD;
             asthma, COPD and rheumatoid arthritis.&#xD;
&#xD;
          -  Unstable body weight (weight gain or loss &gt; 3 kg in the past three months)&#xD;
&#xD;
          -  Impairment of renal function, as evidenced by increased serum creatinine &gt;150 mmol/L&#xD;
&#xD;
          -  Hepatic diseases as manifested by ALT, AST, GGT, total bilirubin or ALP &gt; 2 times the&#xD;
             upper limit of normal&#xD;
&#xD;
          -  CRP values &gt; 8.0 mg/mL&#xD;
&#xD;
          -  Abuse of drugs and/or alcohol&#xD;
&#xD;
          -  Participation in another biomedical study within 1 month prior to the start of this&#xD;
             study&#xD;
&#xD;
          -  Having donated blood (as blood donor) within 1 month prior to start of this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald P. Mensink, Prof. Dr. Ir.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University, Department of Human Biology</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <name_title>Ronald P. Mensink, Prof. Dr. Ir.</name_title>
    <organization>Maastricht University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

